Sensible Biotechnologies, an Oxford, UK- and Bratislava, Slovakia-based mRNA platform company, raised $4.2M in Pre-Seed funding.
The round was led by BlueYard Capital, with participation from Y Combinator, Amino Collective, Civilization Ventures, Recode Health Ventures, and ZAKA. In addition, Florian Schuster, Jason C. Foster and other life science executives are investing as angels.
The company intends to use the funds to accelerate the development of its cell-based platform for cost-efficient manufacturing of mRNA.
Led by CEO Miroslav Gasparek, Sensible Biotechnologies is building a cell-based platform for the production of mRNA. Its platform is focused on mRNA aspect and process for the development of therapeutics and vaccines. Sensible aims to become an integral part of the biomanufacturing infrastructure and biosecurity framework.
FinSMEs
06/04/2023